Literature DB >> 14636179

Adenosine A2A receptor gene disruption provokes marked changes in melanocortin content and pro-opiomelanocortin gene expression.

S Jégou1, M El Yacoubi, L Mounien, C Ledent, M Parmentier, J Costentin, J-M Vaugeois, H Vaudry.   

Abstract

A2A receptor knockout (A2AR-/-) mice are more anxious and aggressive, and exhibit reduced exploratory activity than their wild-type littermates (A2AR+/+). Because alpha-melanocyte-stimulating hormone (alpha-MSH) influences anxiety, aggressiveness and motor activity, we investigated the effect of A2AR gene disruption on alpha-MSH content in discrete brain regions and pro-opiomelanocortin (POMC) expression in the hypothalamus and pituitary. No modification in alpha-MSH content was observed in the hypothalamus and medulla oblongata where POMC-expressing perikarya are located. In the arcuate nucleus of the hypothalamus, POMC mRNA levels were not affected by A2AR disruption. Conversely, in A2AR-/- mice, a significant increase in alpha-MSH content was observed in the amygdala and cerebral cortex, two regions that are innervated by POMC terminals. In the pars intermedia of the pituitary, A2AR disruption provoked a significant reduction of POMC mRNA expression associated with a decrease in alpha-MSH content. By contrast, in the anterior lobe of the pituitary, a substantial increase in POMC mRNA and adrenocorticotropin hormone concentrations was observed, and plasma corticosterone concentration was significantly higher in A2AR-/- mice, revealing hyperactivity of their pituitary-adrenocortical axis. Together, these results suggest that adenosine, acting through A2A receptors, may modulate the release of alpha-MSH in the cerebral cortex and amygdala. The data also indicate that A2A receptors are involved in the control of POMC gene expression and biosynthesis of POMC-derived peptides in pituitary melanotrophs and corticotrophs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14636179     DOI: 10.1111/j.1365-2826.2003.01116.x

Source DB:  PubMed          Journal:  J Neuroendocrinol        ISSN: 0953-8194            Impact factor:   3.627


  7 in total

Review 1.  Ion channels and signaling in the pituitary gland.

Authors:  Stanko S Stojilkovic; Joël Tabak; Richard Bertram
Journal:  Endocr Rev       Date:  2010-07-21       Impact factor: 19.871

Review 2.  Adenosine A2A receptors in ventral striatum, hypothalamus and nociceptive circuitry implications for drug addiction, sleep and pain.

Authors:  S Ferré; I Diamond; S R Goldberg; L Yao; S M O Hourani; Z L Huang; Y Urade; I Kitchen
Journal:  Prog Neurobiol       Date:  2007-05-01       Impact factor: 11.685

Review 3.  Modulators of nucleoside metabolism in the therapy of brain diseases.

Authors:  Detlev Boison
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

4.  Adenosine A(2A) receptors in psychopharmacology: modulators of behavior, mood and cognition.

Authors:  Hai-Ying Shen; Jiang-Fan Chen
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

5.  Melanocortins mimic the effects of leptin to restore reproductive function in lean hypogonadotropic ewes.

Authors:  Kathryn Backholer; Marissa Bowden; Kevin Gamber; Christian Bjørbaek; Javed Iqbal; Iain J Clarke
Journal:  Neuroendocrinology       Date:  2009-11-18       Impact factor: 4.914

Review 6.  Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders.

Authors:  Rodrigo A Cunha; Sergi Ferré; Jean-Marie Vaugeois; Jiang-Fan Chen
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

7.  The caffeine-binding adenosine A2A receptor induces age-like HPA-axis dysfunction by targeting glucocorticoid receptor function.

Authors:  Vânia L Batalha; Diana G Ferreira; Joana E Coelho; Jorge S Valadas; Rui Gomes; Mariana Temido-Ferreira; Tatiana Shmidt; Younis Baqi; Luc Buée; Christa E Müller; Malika Hamdane; Tiago F Outeiro; Michael Bader; Sebastiaan H Meijsing; Ghazaleh Sadri-Vakili; David Blum; Luísa V Lopes
Journal:  Sci Rep       Date:  2016-08-11       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.